Business Development
Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
Hyphens Pharma Pte. Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates
On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China's leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand their strategic collaboration.
Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
Ingelheim, Germany, Tokyo, Japan and Cambridge, UK, 11 March 2024 – Today, Boehringer Ingelheim and Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) announced they have entered a ... Read more
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
Under the terms of the agreement, Arcutis will receive an upfront payment of $25 million, and potentially an additional $40 million if certain regulatory and sales milestones are achieved. Arcutis is also eligible to receive tiered, low double-digit percentage royalties.
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc.
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
I-Mab (the "Company") (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd. (the "Hangzhou Company"), an unconsolidated affiliate of the Company, and a group of China-based investors to divest the Company's assets and business operations in China.
LianBio Announces Completion of Strategic Review
The Company currently anticipates a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024.
Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Under these agreements, Brii Bio will issue a $2.5 million promissory note to VBI initially.
基石药业对外战略合作再下一城 携手艾力斯共同开发普吉华®中国市场 | 会员动态
根据协议，基石药业将获得首付款和后续的研发里程碑付款，并将继续获得普吉华®在中国大陆的销售收入，艾力斯将从基石药业收取服务费。这是基石药业继与三生制药达成Nofazinlimab（抗PD-1单抗）在中国大陆地区战略合作和独家许可协议后，本月内达成的第二起战略合作。
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases
ccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments.
